Clinical Trial Update: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and efficacy of obinutuzumab, polatuzumab vedotin, and atezolizumab in relapsed/refractory follicular lymphoma and rituximab, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Obinutuzumab (obinutuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-11-05